MJNA

Medical Marijuana Inc earns a Neutral rating, supported by a composite score in the low-40s and conviction of two out of five. Regulatory is the strongest pillar, scoring just below 50, with an 80 enforcement subscore and a neutral jurisdiction posture offsetting weak filing cadence. Fundamentals follows closely in the upper-40s, driven by exceptional gross-margin economics, positive EBITDA and a stable financial condition, while severe revenue contraction and negligible market-cap support constrain the contribution. Market ranks lower at 40 because no quote was available through institutional pricing feeds. Editorial is weakest at 30, reflecting no newsroom or brief activity in CIN newsroom coverage.

Licensed fundamentals data show year-over-year revenue falling by approximately 47%, the central weakness behind the low-single-digit revenue-growth subscore. Gross margin approached 79%, producing the maximum gross-margin subscore, but operating margin remained negative at roughly 12%, confirming that strong product-level economics have not translated into operating profitability. EBITDA was positive at about $1.45 million, while net income totaled approximately $8.79 million, supporting the stable financial classification and a strong cash-runway subscore. Market capitalization stood near $2.45 million, generating no support from the size tier. Primary regulatory filings show no dated latest filing, while the prior 90-day and 180-day windows contained no recorded regulatory events or enforcement hits. That combination explains the strong enforcement result but weak cadence score.

The clearest rerating catalyst sits within the regulatory pillar because it already leads the framework despite deficient cadence. A new primary regulatory filing would add current disclosure, improve the weakest component inside the strongest pillar and provide a firmer basis for assessing whether high gross margin and positive EBITDA can persist alongside contracting revenue and negative operating margin. Additional CIN newsroom coverage could lift editorial visibility, while restored pricing availability could sharpen the market assessment, but neither carries the same direct scoring leverage as renewed filing activity. The single most important signal to watch is the appearance of a current primary regulatory filing that restores cadence and validates the operating data.